Novo Nordisk supply of Wegovy stabilizes as new capacity comes online
Decision brief
Answer first · skim in under a minute
Novo Nordisk says Wegovy supply is stabilizing as FDA-determined shortages of Wegovy and Ozempic are resolved. The company is also investing $4.1 billion to expand manufacturing capacity in Clayton, North Carolina.
Novo Nordisk supply Wegovy stabilizes in regulatory terms after the FDA determined on February 21, 2025 that the U.S. semaglutide injection shortage for Wegovy and Ozempic is resolved. The company had already committed $4.1 billion to expand fill-finish capacity in Clayton, North Carolina, signaling a multi-year manufacturing build behind the shortage exit.
Contents10 sections
Key Takeaways
- FDA declared the Wegovy/Ozempic (semaglutide injection) shortage resolved on February 21, 2025, after reviewing Novo Nordisk production and inventory data.
- Wegovy first entered FDA’s shortage list in March 2022; Ozempic followed in August 2022.
- Novo announced a $4.1 billion second fill-finish plant in Clayton, N.C., on June 24, 2024 (~1,000 jobs; completion 2027–2029).
- Shortage resolution does not guarantee zero local stockouts; FDA still monitors supply and demand.
What did the FDA decide about Novo Nordisk supply of Wegovy?
In a February 21, 2025 declaratory order, FDA stated that the semaglutide injection product shortage is resolved. The agency concluded Novo Nordisk’s supply is meeting or exceeding demand and that inventory and semi-finished reserves support projected demand, based on manufacturer submissions summarized in the FDA order PDF.
Novo Nordisk separately said via PR Newswire that FDA’s assessment confirms U.S. supply meets or exceeds current and projected nationwide demand for all doses of Wegovy and Ozempic.
How long had Wegovy been on the FDA shortage list?
FDA’s order notes Wegovy was first added to the drug shortage list in March 2022 and Ozempic in August 2022. That multi-year shortage status shaped compounding rules, payer debates, and investor modeling of GLP-1 volume.
Removing shortage status changes the legal and commercial context for compounded semaglutide copies. It does not, by itself, publish Novo’s confidential unit-level inventory figures, which FDA redacted from the public order.
What new manufacturing capacity is Novo building in the U.S.?
On June 24, 2024, Novo Nordisk announced plans to invest $4.1 billion (about DKK 27 billion) to build a second fill-and-finish manufacturing facility in Clayton, North Carolina, according to a GlobeNewswire company release.
- About 1.4 million square feet of aseptic fill-finish space
- Roughly 1,000 new jobs atop nearly 2,500 regional employees
- Construction completion targeted between 2027 and 2029 (Reuters)
- 2024 production investment plan cited at about $6.8 billion company-wide versus $3.9 billion the prior year
Why does fill-finish capacity matter for Wegovy supply?
Fill-finish—sterile filling and assembly of injection pens—has been a bottleneck as demand for once-weekly semaglutide surged after Wegovy’s U.S. launch. Expanding Clayton’s finished-goods footprint is meant to raise output of current and future injectable chronic-disease products, not only starter doses.
Investors should separate the February 2025 shortage exit (a regulatory supply finding) from the 2027–2029 Clayton timeline (future capacity that was not required for FDA’s immediate shortage determination).
What should BD and market-access teams watch next?
Watch FDA’s ongoing shortage list updates, wholesale inventory signals, and any renewed shortage listing if demand again outruns supply. Also track how payers and states treat compounded semaglutide after the shortage ends.
Competitive supply from other incretin products can still constrain patient starts even when Novo’s branded semaglutide is no longer formally “in shortage.”
What remains unproven?
Public FDA and company materials do not disclose dose-level pharmacy fill rates by ZIP code or guarantee that every wholesaler depot is continuously stocked. Claims that “supply has fully stabilized everywhere” go beyond the national determination FDA published.
Related NovaPharma coverage
- GLP-1 usage statistics: what the data shows
- Obesity rates in America by year
- AbbVie Cerevel acquisition closes
Frequently Asked Questions
When did FDA say the Wegovy and Ozempic shortage ended?
On February 21, 2025, FDA determined the semaglutide injection product shortage for Wegovy and Ozempic is resolved, finding Novo Nordisk supply meets or exceeds current and projected U.S. demand.
What manufacturing investment did Novo announce in Clayton?
On June 24, 2024, Novo Nordisk announced a $4.1 billion investment to build a second fill-and-finish facility in Clayton, North Carolina, adding about 1.4 million square feet and roughly 1,000 jobs, with completion targeted between 2027 and 2029.
Does a resolved shortage mean every pharmacy is stocked?
No. FDA’s shortage resolution is a national supply-versus-demand determination. Localized, intermittent disruptions can still occur as product moves through wholesale and retail channels.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Wegovy.
Unlock full calendar →Novo Nordisk pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
